Tonix Pharmaceuticals Hld

Tonix Pharmaceuticals Holding Corp. is a clinical-stage biopharmaceutical company, which focuses on the discovery, acquisition, and development of small molecules and biologics to treat and prevent human disease and alleviate suffering. Its portfolio includes TNX-102 SL, TNX-601, TNX-801, and TNX-1800. The company was founded by Seth Lederman and Donald W. Landry on November 16, 2007 and is headquartered in Chatham, NJ.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

NEW YORK, Aug.  06, 2020  (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for the initiation of a Phase 2 proof-of-concept study using TNX-102 SL for treatment of alcohol use disorder (AUD). The program in AUD is expected to qualify for the 505(b)(2) pathyway for FDA approval.

Tonix Pharmaceuticals Announces Clearance of IND for TNX-102 SL for Treatment of Alcohol Use Disorder

Ideanomics Inc

Electrameccanica

XpresSpa Group

Zomedica

Penny stocks will always be risky. That said, with the huge disconnect we're seeing in the markets, now may be a time to gamble.

The Top 8 Penny Stocks to Buy for August Uncertainty

CleanSpark

Their share prices are predicted to bounce back strongly

Analysts Recommend Buying These 2 Falling Knives

NEW YORK, July  21, 2020  (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced that it is rescheduling the date of the Company’s Special Meeting of Stockholders (the “Special Meeting”) previously scheduled for Friday, June 26, 2020, to Friday, August 28, 2020, at 11:00 a.m., Eastern Time. In connection with the change of the Special Meeting date, the record date for determining stockholders entitled to attend and vote at the Special Meeting has been changed to the close of business on July 15, 2020. 

Tonix Pharmaceuticals Holding Corp. Announces Rescheduling of Special Meeting of Stockholders

ACADIA Pharma

CytoSorbents

Genworth Financial

Hibbett Sports

Limelight Networks

New Age Beverages

Qiwi

The S&P 500 closing up 0.8% at 2,251.84 and with the NASDAQ closing up 2.5% at 10,767.09, many investors are wondering how stocks keep rising despite the major recession in the time of a COVID-19 pandemic.

9 Stocks With Massive Moves in Monday’s After-Hours Session

Dissecting the Immune Response to SARS-CoV-2 in Healthy Recovered or Asymptomatic Volunteers May Lead to Biomarkers for Tailoring COVID-19 Vaccines and Therapeutics

Tonix Pharmaceuticals Announces Research Collaboration to Develop Precision Medicine Techniques for COVID-19 Vaccines and Therapeutics

NEW YORK, July  15, 2020  (GLOBE NEWSWIRE) -- TONIX PHARMACEUTICALS HOLDING CORP. (NASDAQ: TNXP) (“Tonix” or the “Company”), a clinical-stage biopharmaceutical company, today announced the closing of its previously announced registered direct offering, with gross proceeds of approximately $10.5 million before deducting fees and other estimated offering expenses.

Tonix Pharmaceuticals Holding Corp. Closes $10.5 Million Common Stock Registered Direct Offering

NEW YORK, July  13, 2020  (GLOBE NEWSWIRE) -- TONIX PHARMACEUTICALS HOLDING CORP. (NASDAQ: TNXP) (“Tonix” or the “Company”), a clinical-stage biopharmaceutical company, today announced it has entered into a securities purchase agreement with institutional investors for the purchase and sale of 20,940,000 shares of common stock, par value $0.001 per share at an offering price of $0.50 per share, pursuant to a registered direct offering. The gross proceeds of the offering will be approximately $10.5 million before deducting fees and other estimated offering expenses. The closing of the registered direct offering is expected to take place on or about July 15, 2020, subject to the satisfaction of customary closing conditions. 

Tonix Pharmaceuticals Holding Corp. Prices $10,500,000 Common Stock Offering

Research to Develop Live Replicating Vaccine (TNX-2300) to Protect Against COVID-19 Based on Bovine Parainfluenza Virus

Tonix Pharmaceuticals Enters into Research and Exclusive License Option Agreement with Kansas State University to Develop Vaccine Against COVID-19

Target Enrollment Completed Ahead of Schedule

Tonix Pharmaceuticals Completes Enrollment in Phase 3 RELIEF Trial of TNX-102 SL for Management of Fibromyalgia

Tonix's Advanced Development Center Will House Laboratories Dedicated to Process and Analytical Development

Tonix Pharmaceuticals Plans Massachusetts R&D Facility to Accelerate Clinical Development of Vaccines and Protein-Based Therapeutics

Topline Results Expected Fourth Quarter 2020 Due to Faster than Previously Projected Enrollment

Tonix Pharmaceuticals Announces Enrollment of Phase 3 RELIEF Trial of TNX-102 SL for Management of Fibromyalgia is Ahead of Schedule

TNX-1700 (Stabilized Recombinant Trefoil Factor 2) (rTFF2-CTP) Enhances Anti-tumor Activity of PD-1 blockade in Mouse Models of Colorectal Cancer

Tonix Pharmaceuticals Announces Results from Preclinical Study of TNX-1700 Presented in a Poster at AACR Virtual Annual Meeting 2020

Plan to Produce Blueprint of How the Human Immune System Responds to Infection Caused by SAR-CoV-2, the Virus that Causes COVID-19

Tonix Pharmaceuticals and Southern Research Announce Expansion of COVID-19 Vaccine Collaboration

NEW YORK, June  17, 2020  (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced that preclinical results of TNX-1700 (rTFF2) will be presented in a poster at the American Association of Cancer Research (AACR) Virtual Annual Meeting II. The meeting is being held June 22-24, 2020.

Tonix Pharmaceuticals Announces that Results from Preclinical Studies of TNX-1700 Will be Presented in a Poster at the AACR Virtual Annual Meeting 2020

TNX-1900 Intranasal Oxytocin has the Potential to Treat Migraine and Craniofacial Pain TNX-1900 Intranasal Oxytocin has the Potential to Treat Migraine and Craniofacial Pain

Tonix Pharmaceuticals Announces Acquisition of Non-Addictive Migraine and Pain Treatment Programs from Trigemina and Assumption of License

NEW YORK, June  10, 2020  (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced the appointment of Richard H. Bagger to its Board of Directors, effective as of June 9, 2020. Mr. Bagger assumes the seat held by John Rhodes, who has stepped down from the position of company director that he has held since 2011.

Tonix Pharmaceuticals Announces Appointment of Richard H. Bagger to Board of Directors

Collaboration includes Development of Manufacturing Processes and to Supply Clinical Trial Material to Support Tonix’s Development of TNX-1800 Collaboration includes Development of Manufacturing Processes and to Supply Clinical Trial Material to Support Tonix’s Development of TNX-1800

Tonix Pharmaceuticals Announces FUJIFILM Diosynth Biotechnologies to be Manufacturing Partner for COVID-19 Vaccine Candidate TNX-1800

NEW YORK, May  21, 2020  (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, posted two posters for the American Society of Clinical Psychopharmacology (ASCP) 2020 Annual Meeting to be held online virtually on May 29-30, 2020. The posters can be found on the  Scientific Presentations  page of Tonix’s website.

Tonix Pharmaceuticals Posted Results from Pharmacokinetic Analyses of TNX-102 SL and TNX-601 CR in Advance of Virtual Poster Presentations at the American Society of Clinical Psychopharmacology

NEW YORK, May  19, 2020  (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced the appointment of Herbert Harris, M.D., Ph.D., as its new Executive Vice President, Translational Medicine, effective May 15, 2020. In this role, Dr. Harris will focus on advancing Tonix’s pre-clinical pipeline, including the potential COVID-19 vaccine into the clinic, as well as participate in Tonix’s ongoing clinical programs.

Tonix Pharmaceuticals Announces Appointment of Herbert Harris, M.D., Ph.D., as Executive Vice President, Translational Medicine

Four Potential Vaccines in Development to Protect Against New Coronavirus Disease 2019 (COVID-19) Based on the Company’s Horsepox Virus Vaccine Platform

Tonix Pharmaceuticals Reports First Quarter 2020 Financial Results and Operational Highlights

Enrollment Continues in Phase 3 RELIEF Study, with Interim Results of the First 50 Percent of Participants Expected in September 2020

Tonix Pharmaceuticals Achieves 50 Percent Enrollment in Phase 3 RELIEF Study of TNX-102 SL (Cyclobenzaprine HCl Sublingual Tablets) for Management of Fibromyalgia

NEW YORK, April  20, 2020  (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company) announced today that Seth Lederman, M.D., President and Chief Executive Officer of Tonix, will be conducting a virtual presentation in conjunction with the Planet MicroCap Showcase Virtual Investor Conference on Wednesday, April 22, 2020, at 12:00 p.m. ET.

Tonix Pharmaceuticals to Deliver Virtual Presentation and Participate in Panel Discussion for Planet MicroCap Showcase Virtual Investor Conference 2020

NEW YORK, March  03, 2020  (GLOBE NEWSWIRE) -- TONIX PHARMACEUTICALS HOLDING CORP. (NASDAQ: TNXP) (“Tonix” or the “Company”), a clinical-stage biopharmaceutical company, today announced the closing of its previously announced registered direct offering, with gross proceeds of $16,005,000 before deducting fees and other estimated offering expenses.

Tonix Pharmaceuticals Holding Corp. Closes $16,005,000 Common Stock Registered Direct Offering

NEW YORK, Feb.  28, 2020  (GLOBE NEWSWIRE) -- TONIX PHARMACEUTICALS, INC. (NASDAQ: TNXP) (“Tonix” or the “Company”), a clinical-stage biopharmaceutical company, today announced it has entered into a securities purchase agreement with institutional investors for the purchase and sale of 14,550,000 shares of common stock, par value $0.001 per share at an offering price of $1.10 per share, pursuant to a registered direct offering, priced at-the-market under Nasdaq rules. The gross proceeds of the offering will be $16,005,000 before deducting fees and other estimated offering expenses. The closing of the registered direct offering is expected to take place on or about March 3, 2020, subject to the satisfaction of customary closing conditions.

News for Tonix Pharmaceuticals Hld Stock (TNXP)